Viking Therapeutics Inc (VKTX)

[staccani]

The difference in market cap between MDGL and VKTX is almost entirely due to the perceived safety risk. I think people are afraid that the ALT/AST mild elevation in the 14 days ph1b trial may have an impact on ph2 results.
I have also read Zack's small cap research were they stated that the ALT AST elevation was not significant in the 10 mg dose and did not happen in the 5 mg dose (the two used in ph2) and even in the highest 40 mg dose it went back to normal levels by the end of the 14 days trial (strange).
Does anybody have more precise data about patients baseline , peak, average ALT and AST values per each dose in ph1b?
I guess if this turns out not to be an issue, VK2809 then may be a better drug than MDGL's, since more effective